

ABSTRACT

The present invention relates to the technical field of medicines, and in particular, to a mesylate crystalline form of a TAM family kinase and/or CSF1R kinase and/or NTRK inhibitor shown in a formula (I), a preparation method therefor and a pharmaceutical use thereof.

